AI Article Synopsis
- CAR-T cell therapy shows great success in treating blood cancers but faces challenges when targeting solid tumors due to the tumor microenvironment (TME).
- * The paper explores new research, compares CAR-T therapy with traditional immunotherapy, and identifies obstacles like immunosuppressive factors and metabolic issues that limit CAR-T effectiveness.
- * It also discusses innovative strategies to overcome these challenges and addresses safety management concerns related to CAR-T therapy.
Article Abstract
Chimeric antigen receptor (CAR-T) cell therapy has been widely used in hematological malignancies and has achieved remarkable results, but its long-term efficacy in solid tumors is greatly limited by factors such as the tumor microenvironment (TME). In this paper, we discuss the latest research and future views on CAR-T cell cancer immunotherapy, compare the different characteristics of traditional immunotherapy and CAR-T cell therapy, introduce the latest progress in CAR-T cell immunotherapy, and analyze the obstacles that hinder the efficacy of CAR-T cell therapy, including immunosuppressive factors, metabolic energy deficiency, and physical barriers. We then further discuss the latest therapeutic strategies to overcome these barriers, as well as management decisions regarding the possible safety issues of CAR-T cell therapy, to facilitate solutions to the limited use of CAR-T immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10728652 | PMC |
| http://dx.doi.org/10.3389/fonc.2023.1288383 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!